Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

September 02, 2015 11:54 PM ET

Life Sciences Tools and Services

Company Overview of Personalis, Inc.

Company Overview

Personalis, Inc. provides human genome analysis services for clinical medicine. It offers genome sequencing and interpretation services for research and medical communities. The company was incorporated in 2011 and is based in Palo Alto, California with a subsidiary operation in the United Kingdom.

530 Lytton Avenue

2nd Floor

Palo Alto, CA 94301

United States

Founded in 2011

Key Executives for Personalis, Inc.

Co-Founder, Chief Executive Officer and Director
Compensation as of Fiscal Year 2015.

Personalis, Inc. Key Developments

Personalis, Inc. Presents at UBS Genomics 2.0 Summit, Aug-13-2015 12:45 PM

Personalis, Inc. Presents at UBS Genomics 2.0 Summit, Aug-13-2015 12:45 PM. Venue: The St. Regis Deer Valley, Park City, Utah, United States. Speakers: John West, Co-Founder, Chief Executive Officer and Director.

Personalis, Inc. Receives Contract from US Department of Veterans Affairs for Clinical Cancer Genomic Testing and Research Analysis

Personalis, Inc. announced that the company has been awarded a contract to provide research and clinical genomic testing for cancer tumors and biopsies, by the US Department of Veterans Affairs (VA) New England Veterans Integrated Service Network 1 (VISN 1) Precision Oncology Program. Personalis will perform clinical cancer testing and research services based on its ACE Extended Cancer Panel for DNA and RNA Analysis. This provides comprehensive and detailed genomic profiling of solid tumors and identification of potential targeted treatment options for VA New England Healthcare System patients. By combining DNA and RNA analysis, and covering over 1,500 genes, Personalis™ testing provides comprehensive data for both clinical testing and ongoing research use at the VA. To further support the VISN 1 Precision Oncology Program and its research goals, Personalis is also providing its ACE Exome for Cancer Research and its ACE Whole Transcriptome for Cancer Research, again pairing DNA with RNA analysis. Personalis will process this sequencing data using its proprietary cancer informatics pipeline. Personalis has also subcontracted N-of-One, Inc, to augment clinical reporting with additional curation. The program plans to begin with samples from Non-Small-Cell Lung Cancer patients, and later expand to other cancer types.

Personalis, Inc. Introduces New Services for Cancer Research and Clinical Trials

Personalis, Inc. announced it is launching an expanded portfolio of cancer research solutions based on its ACE (Accuracy and Content Enhanced) sequencing, informatics and content technology platform. Scientists from Personalis presented the new portfolio of cancer research solutions this weekend to attendees at the 2014 American Society of Human Genetics Annual Meeting taking place through Wednesday in San Diego. The ACE Exome for Cancer provides data from the common gene set in the broader context of more than 8,000 medically related genes with augmented coverage, and 20,000 genes overall. The ACE Extended Cancer Panel targets the same broad cancer gene set, but achieves over 500x average sequencing coverage, for optimum sensitivity to alleles from rare cell subpopulations. Personalis offers this end-to-end service starting with a broad range of sample types, including FFPE blocks, Fine Needle Aspirates, core biopsies and fresh frozen tissue. By combining DNA and RNA analysis, Personalis provides a comprehensive tumor genomic profile. DNA and RNA assays are matched to cover the same gene sets, either at the exome level or the panel level. Personalis' cancer data analysis pipeline integrates the DNA and RNA results, providing a more comprehensive understanding than would be possible from either independently. This includes detection of fusion transcripts and allelic expression, as well as gene expression. None of these would be well reported with DNA analysis alone.

Similar Private Companies By Industry

Company Name Region
Prospero Biosciences, LLC United States
Genomic Nanosystems, LLC United States
Novus Biologicals, LLC United States
Development & Research, Inc. United States
Formex, LLC United States

Recent Private Companies Transactions

Private Placement
December 16, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Personalis, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at